PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation ; study protocol for a randomized controlled trial

In early-stage non-small cell lung cancer (NSCLC) without affected lymph nodes detected at staging, surgical resection is still the mainstay of treatment. However, in patients with metastatic mediastinal lymph nodes (pN2) or non-radically resected primary tumors (R1/R2), postoperative radiotherapy (...

Full description

Saved in:
Bibliographic Details
Main Authors: Bütof, Rebecca (Author) , Simon, M. (Author) , Löck, S. (Author) , Troost, E. G. C. (Author) , Appold, S. (Author) , Krause, M. (Author) , Baumann, Michael (Author)
Format: Article (Journal)
Language:English
Published: 20 December 2017
In: Trials
Year: 2017, Volume: 18, Issue: 1, Pages: 1-6
ISSN:1468-6694
DOI:10.1186/s13063-017-2346-0
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13063-017-2346-0
Get full text
Author Notes:R. Bütof, M. Simon, S. Löck, E.G.C. Troost, S. Appold, M. Krause and M. Baumann
Description
Summary:In early-stage non-small cell lung cancer (NSCLC) without affected lymph nodes detected at staging, surgical resection is still the mainstay of treatment. However, in patients with metastatic mediastinal lymph nodes (pN2) or non-radically resected primary tumors (R1/R2), postoperative radiotherapy (possibly combined with chemotherapy) is indicated. So far, investigations about time factors affecting postoperative radiotherapy have only examined the waiting time defined as interval between surgery and start of radiotherapy, but not the overall treatment time (OTT) itself. Conversely, results from trials on primary radio(chemo)therapy in NSCLC show that longer OTT correlates with significantly worse local tumor control and overall survival rates. This time factor of primary radio(chemo)therapy is thought to mainly be based on repopulation of surviving tumor cells between irradiation fractions. It remains to be elucidated if such an effect also occurs when patients with NSCLC are treated with postoperative radiotherapy after surgery (and chemotherapy). Our own retrospective data suggest an advantage of shorter OTT also for postoperative radiotherapy in this patient group.
Item Description:Gesehen am 27.09.2021
Physical Description:Online Resource
ISSN:1468-6694
DOI:10.1186/s13063-017-2346-0